Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown CureVac N.V. CVAC

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.


Top institutional share ownership of CureVac N.V.

Name Shares Shares % change Value Value % change
Bill & Melinda Gates Foundation 1,709,781 0.0% $13,500 -42.1%
VWIGX - Vanguard International Growth Fund Investor Shares 1,694,894 -38.0% $31,864 -30.7%
BlackRock Inc. 974,383 -7.3% $7,678 -46.3%
Millennium Management Llc 536,032 0.3% $4,224 -41.9%
IBB - iShares Nasdaq Biotechnology ETF 409,470 -3.5% $3,227 -44.1%
Goldman Sachs Group Inc 386,976 -41.8% $3,049 -66.3%
Norges Bank 368,406 12.5% $20,122 -16.4%
Marshall Wace, Llp 333,819 0.5% $2,629 -41.9%
Morgan Stanley 319,295 -1.8% $2,517 -43.1%
IEFA - iShares Core MSCI EAFE ETF 289,982 $3,871

Top institutional buyers of CureVac N.V.

Name Shares % change Value % change Shares Value
QCSTRX - Stock Account Class R1 107.9% 24.7% 97,332 $795
Credit Suisse Ag/ 48.9% -13.8% 165,209 $1,302
IDNA - iShares Genomics Immunology and Healthcare ETF 34.3% 2.2% 168,210 $2,187
FSMDX - Fidelity Mid Cap Index Fund 27.3% 12.7% 130,280 $2,226
GNOM - Global X Genomics & Biotechnology ETF 16.4% -39.9% 254,190 $2,535
Norges Bank 12.5% -16.4% 368,406 $20,122
Rafferty Asset Management, LLC 2.5% -40.7% 80,679 $636
Geode Capital Management, Llc 1.5% -41.3% 151,822 $1,196
Marshall Wace, Llp 0.5% -41.9% 333,819 $2,629
Millennium Management Llc 0.3% -41.9% 536,032 $4,224

Top institutional sellers of CureVac N.V.

Name Shares % change Value % change Shares Value
Goldman Sachs Group Inc -41.8% -66.3% 386,976 $3,049
Susquehanna International Group, Llp -40.1% -65.3% 105,001 $827
VWIGX - Vanguard International Growth Fund Investor Shares -38.0% -30.7% 1,694,894 $31,864
BlackRock Inc. -7.3% -46.3% 974,383 $7,678
IBB - iShares Nasdaq Biotechnology ETF -3.5% -44.1% 409,470 $3,227
Morgan Stanley -1.8% -43.1% 319,295 $2,517

Information provided by Fintel.io